Last reviewed · How we verify
PET Tracer
At a glance
| Generic name | PET Tracer |
|---|---|
| Also known as | C11-ER176 |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia (PHASE2)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) (PHASE1)
- Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (PHASE1)
- The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer (PHASE1)
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (PHASE1)
- 18F-mFBG Imaging for Myocardial Sympathetic Innervation (PHASE2)
- Diagnosis of Pheochromocytoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |